2007～2008年新上市抗艾滋病药物

下载PDF

导出

摘要随着艾滋病在世界范围内的泛滥，对艾滋病的预防和治疗已成为一个不容忽视的社会问题和重大的科研课题。本文主要介绍了2007-2008年FDA批准的抗艾滋病药物Maraviroc，Raltegravir，Etravirine的化学成分、作用机制、用法及不良反应等。

作者王丽翟海民李莹

机构地区山东齐都药业有限公司济南宏济堂制药有限责任公司

出处《齐鲁药事》 2009年第7期445-446,共2页 qilu pharmaceutical affairs

关键词人类免疫缺陷病毒抗艾滋病药物抗病毒药物

参考文献11

1Zhan P, Liu X. Designed multiple ligands : an emerging anti-- HIV drug discovery paradigm. Current Pharmaceutical Design, 2009, 35 (15) : 1893- 1917.
2Zhan P, Li Z, Liu X. Sulfanyltriazole/tetrazoles: A Promising Class of HIV-- 1 NNRTIs. Mini-Rev Med Chem, 2009,9 (8) : 1014-1023.
3Erik De Clercq. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. International Journal of Antimicrobial Agents, 2009,33 : 307- 320.
4王德克,蔺红伟,肖凯.Maraviroc和Raltegravir：两种新型的抗HIV药物[J].世界感染杂志,2008,8(5):382-384. 被引量：1
5Lieberman Blum SS, Fung HB, Bandres JC. Maraviroc: a CCRs-receptor antagonist for the treatment of HIV- 1 infection. Clinical Therapeutics, 2008,30 : 1228 - 1250.
6李岩峰,白秋江,赵军.抗HIV感染新药:Raltegravir[J].疑难病杂志,2008,7(5):304-304. 被引量：1
7Cocohoba J,Dong BJ. Raltegravir: The First HIV Integrase Inhibitor. Clinical Therapeutics,2008,30(10) : 1747-1765.
8Iwamoto M, Wenning LA, Pet ry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther,2007,21(8) :22-24.
9马培奇.2008年上半年全球首次批准新药[J].中国医药技术经济与管理,2008,2(12):20-28. 被引量：1
10Schiller DS,Youssef Bessler M. Etravirine:A second-Generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI resistant strains of HIV. Clinical Therapeutics, 2009,31(4) :693-704.

1Kuritzkes D, Kar S, Kirkpatrick P. Maraviroe[J]. Nature Rev Drug Discov, 2008, 7: 15-16.
2A M, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1 [J]. Annu Rev Med. 2007, 58: 445-459.
3Biswas P, Tambussi C,, Lazzarin A. "Access denied? The status of co-receptor inhibition to counter HIV entry"[J]. Expert Opin Pharmacother, 2007, 8 (7): 923-933.
4Food and Drug Administration. FDA labelling information [online] [EB/OL], <http://www. fda.gov/eder/foi/label/2007/022128 lbl.pdf> (2007).
5Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/Aids[J]. Nature Rev Drug Discov, 2005, 4, 236-248.
6Deeks SG, Kar S, Gubemick SI, et al. Raltegravir[J]. Nat Rev Drug Discov, 2008, 7: 117-118.
7Food and Drug Administration. FDA labelling information [online] [EB/oL], <http://www. fda.gov/eder/foi/label/2007/022145 lbl.pdf> (2007).
8Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect Of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study[J]. J Acquit Immune Defic Syndr, 2007, 46(2): 125-133.
9Flexner C. HIV drug development: the next 25 years[J]. Nature Rev Drug Discov, 2007, 6: 959-966.
10Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects [J]. Clin Pharmacol Ther,2007,21 (8) :22-24.

齐鲁药事

2009年第7期

内容加载中请稍等...